All Stories

  1. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

    Article • Drug Design Development and Therapy, August 2015, Dove Medical Press

    Dr Michael Lahn